中国药物警戒 ›› 2025, Vol. 22 ›› Issue (9): 1057-1060.
DOI: 10.19803/j.1672-8629.20241018

• 安全与合理用药 • 上一篇    下一篇

度伐利尤单抗注射液致脓疱型银屑病1例分析

魏盈1, 李文凤1,2, 张宇飞1,2, 侯欣1, 杨彦伟3, 樊永丽1,2,*   

  1. 1河南大学第一附属医院肿瘤科,河南 开封 475000;
    2开封市分子影像与肿瘤分子免疫重点实验室,河南 开封 475000;
    3河南大学第一附属医院药学部,河南 开封 475000
  • 收稿日期:2024-12-23 发布日期:2025-09-22
  • 通讯作者: *樊永丽,女,博士,副教授·硕导,肿瘤临床与基础研究。E-mail: fanyongli1987@163.com
  • 作者简介:魏盈,女,硕士,住院医师,肿瘤临床与基础研究。
  • 基金资助:
    河南省医学科技攻关计划项目（LHGJ20230419）; 河南省医学教育研究项目（Wjlx2022214）

One Case of Pustular Psoriasis Caused by Duvalumab Injection

WEI Ying1, LI Wenfeng1,2, ZHANG Yufei1,2, HOU Xin1, YANG Yanwei3, FAN Yongli1,2,*   

  1. 1Department of Oncology, the First Affiliated Hospital of Henan University, Kaifeng Henan 475000, China;
    2Kaifeng Key Laboratory of Molecular Imaging and Tumor Molecular Immunity, Kaifeng Henan 475000, China;
    3Department of Pharmacy, the First Affiliated Hospital of Henan University, Kaifeng Henan 475000, China
  • Received:2024-12-23 Published:2025-09-22

PDF (PC)

42

摘要： 目的 探讨度伐利尤单抗注射液诱发脓疱型银屑病的临床特征及潜在机制,为临床安全用药提供参考。方法 对1例接受度伐利尤单抗注射液治疗的非小细胞肺癌发生脓疱型银屑病患者的诊治经过进行回顾性分析,结合文献探讨其发生机制及治疗方法。结果 经关联性分析,该患者出现免疫相关皮肤不良反应与度伐利尤单抗注射液很可能相关,患者经停药并给予古塞奇尤单抗治疗后好转。结论 文献显示度伐利尤单抗注射可能通过激活IL-36/IL-17炎症轴诱发脓疱型银屑病,临床需警惕此类免疫相关不良事件,做到尽早识别并及时干预。

关键词: PD-1/PDL-1抑制剂, 度伐利尤单抗, 注射液, 脓疱型银屑病, 免疫相关不良反应, 药品不良反应

Abstract: Objective To analyze the clinical characteristics and mechanisms of pustular psoriasis caused by duvalumab injection so as to provide a reference for rational use of duvalumab injection. Methods One case of pustular psoriasis (PP) that was considered to have been caused by duvalumab was analyzed. Related literature was reviewed while the process of diagnosis and treatment, possible mechanisms, clinical manifestations and treatment regimens were summarized. Results Correlation analysis suggested that the immune-related adverse reactions of the skin in this patient were likely induced by durvalumab injection. After effective treatment with guselkumab and discontinuation of durvalumab injection, the patient’s symptoms of PP were relieved. Conclusion Durvalumab may induce PP via activation of the IL-36/IL-17 inflammatory axis. Clinicians should be alert to such immune-related adverse events (irAEs) to ensure early detection and quick interventions.

Key words: PD-1/PDL-1 Inhibitors, Duvalumab, Injection, Pustular Psoriasis, irAEs, Adverse Drug Reactions

中图分类号: